Match!
Robert H. Dworkin
University of Rochester
352Publications
74H-index
28.1kCitations
Publications 355
Newest
Abstract The estimated probability of progressing from phase 3 analgesic clinical trials to regulatory approval is approximately 57%, suggesting that a considerable number of treatments with phase 2 trial results deemed sufficiently successful to progress to phase 3 do not yield positive phase 3 results. Deficiencies in the quality of clinical trial conduct could account for some of this failure. An Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) meeting was ...
Source
#1Bethea A. Kleykamp (UR: University of Rochester)
#2Marta De Santis (NIDA: National Institute on Drug Abuse)
Last.Eric C. Strain (Johns Hopkins University)H-Index: 43
view all 13 authors...
Abstract Introduction The subjective experience of drug craving is a prominent and common clinical phenomenon for many individuals diagnosed with opioid use disorder (OUD), and could be a valuable clinical endpoint in medication development studies. The purpose of this scoping review is to provide an overview and critical analysis of opioid craving assessments located in the published literature examining OUD. Method Studies were identified through a search of PubMed, Embase, and PsychInfo datab...
Source
#1Anna Xu (UPenn: University of Pennsylvania)H-Index: 1
#2Bart Larsen (UPenn: University of Pennsylvania)H-Index: 1
Last.Theodore D. Satterthwaite (UPenn: University of Pennsylvania)H-Index: 44
view all 13 authors...
Characterizing a reliable, pain-related neural signature is critical for translational applications. Many prior fMRI studies have examined acute pain-related brain activation in healthy participants. However, synthesizing these data to identify convergent patterns of activation can be challenging due to the heterogeneity of experimental designs and samples. To address this challenge, we conducted a comprehensive meta-analysis of fMRI studies of stimulus-induced pain in healthy participants. Foll...
1 CitationsSource
#1Jennifer S. Gewandter (URMC: University of Rochester Medical Center)H-Index: 18
#2Amber S. Kleckner (URMC: University of Rochester Medical Center)H-Index: 4
Last.Karen M. Mustian (URMC: University of Rochester Medical Center)H-Index: 39
view all 11 authors...
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication of many chemotherapies. We investigated the feasibility of using health plan claims and administrative data to identify CIPN occurrence by comparing patients who received neurotoxic and non-neurotoxic chemotherapies.
Source
#1Shannon M. Smith (URMC: University of Rochester Medical Center)H-Index: 15
#2Maurizio Fava (Harvard University)H-Index: 106
Last.Robert H. DworkinH-Index: 74
view all 7 authors...
Abstract Recent research has suggested that the magnitudes of analgesic treatment effects estimated in clinical trials have decreased over time. Implications of these findings for future sample size calculations and clinical trial research designs have not been addressed. In this article, we examine the standardized effect size (SES) for average pain intensity (API) and worst pain intensity (WPI) outcomes from randomized clinical trials (RCTs) of analgesic treatments shown to be efficacious for ...
Source
Last.Michael P. McDermottH-Index: 79
view all 5 authors...
AbstractIt is often assumed that there are two types of pain patients: those who respond well to efficacious pain therapies and those who do not respond at all, with few people in the middle. This assumption is based on research that claims that changes in pain intensity have a bimodal distribution.
Source
#1Jennifer S. Gewandter (UR: University of Rochester)H-Index: 18
#2Christopher H. Gibbons (UR: University of Rochester)H-Index: 29
Last.Roy Freeman (UR: University of Rochester)H-Index: 1
view all 16 authors...
Distal symmetrical axonal polyneuropathy (DSP) is due to injury to peripheral sensory, motor, and autonomic nerve fibers, resulting in distal predominant sensory loss, pain, and gait instability. DSP occurs as a complication of multiple medical conditions including diabetes or HIV, or following exposure to various toxins such as chemotherapy. It affects at least 10% of the United States population. Few treatments for DSP are approved by regulatory agencies. Reliable and responsive outcome measur...
Source
#1Jennifer S. Gewandter (UR: University of Rochester)H-Index: 18
#2Michael P. McDermott (UR: University of Rochester)H-Index: 79
Last.Robert H. Dworkin (UR: University of Rochester)H-Index: 74
view all 11 authors...
1 CitationsSource
#1Michael L. Kent (Duke University)H-Index: 53
#2Patrick J. Tighe (UF: University of Florida)H-Index: 14
Last.Robert H. Dworkin (URMC: University of Rochester Medical Center)H-Index: 74
view all 5 authors...
Source
Last.Robert H. DworkinH-Index: 74
view all 7 authors...
Source
12345678910